Reovirus as a novel oncolytic agent

Journal of Clinical Investigation

Volumn 105, Issue 8, 2000, Pages 1035-1038

  Norman, Kara L ^a   Lee, Patrick W K ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CANCER THERAPY; CYTOTOXICITY; GENE ACTIVATION; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; REOVIRUS; REVIEW; VIRUS REPLICATION;

EID: 0034006184     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9871     Document Type: Review

References (33)

1. Strong, J.E., Coffey, M.C., Tang, D., Sabinin, P., and Lee, P.W. 1998. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 17:3351-3362.
2. Rosen, L., Hovis, J., Mastrota, F.M., Bell, J.A., and Huebner, R.J. 1960. Observations on a newly recognized virus (Abney) of the reovirus family. American Journal of Hygiene, 71:258-265.
3. Rosen, L., Evans, H.E., and Spickard, A. 1963. Reovirus infections in human volunteers. American Journal of Hygiene. 77:29-37.
4. Bos, J.L. 1989. ras oncogenes in human cancer: a review [erratum 1990, 50:1352]. Cancer Res. 49:4682-4689.
5. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
6. Coffey, M.C., Strong, J.E., Forsyth, P.A., and Lee, P.W. 1998. Reovirus therapy of tumors with activated Ras pathway. Science. 282:1332-1334.
7. Tyler, K.L., and Fields, B.N. 1996. Reoviruses. In Fields virology. B.N. fields, D.M. Knipe, and P.M. Howley, editors. Lippincott-Raven. Philadelphia, Pennsylvania, USA. 1597-1623.
8. Sabin, A.B. 1959. Reoviruses: a new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science. 130:1387-1389.
9. Jackson, G.G., and Muldoon, R.L. 1973. Viruses causing common respiratory infection in man. IV. Reoviruses and adenoviruses. J. Infect. Dis. 128:811-833.
10. Minuk, G.Y., Paul, R.W., and Lee, P.W. 1985. The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J. Med. Virol. 16:55-60.
11. Minuk, G.Y., et al. 1987. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 5:8-13.
12. Hashiro, G., Loh, P.C. and Yau, J.T. 1977. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch. Virol. 54:307-315.
13. Duncan, M.R., Stanish, S.M., and Cox, D.C. 1978. Differential sensitivity of normal and transformed human cells to reovirus infection. J. Virol. 28:444-449.
14. Strong, J.E., Tang, D., and Lee, P.W. 1993. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology. 197:405-411.
15. Strong, J.E., and Lee. P.W. 1996. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J. Virol. 70:612-616.
16. Campbell, S.L., Khosravi-Far, R., Rossman, K.L., Clark, G.J., and Der, C.J. 1998. Increasing complexity of Ras signaling. Oncogene. 17:1395-1413.
17. Bischoff, J.R., and Samuel, C.E. 1989. Mechanism of interferon action. Activation ot the human P1/cIF-2 alpha protein kinase by individual reovirus s-class mRNAs: s1 mRNA is a potent activator relative to s4 mRNA. Viralogy. 172:106-115.
18. Thomis, D.C., and Samuel, C.E. 1993. Mechanism of interferon action: evidence for intermolecular autophosphorylation and autoactivation of the interferon-induced, RNA dependent protein kinase PKR. J. Virol. 67:7695-7700.
19. Panniers, R., and Henshaw, L.C. 1983. A GDP/GTP exchange factor essential for eukaryotic initiation factor 2 cycling in Ehrlich ascites tumor cells and its regulation by eukaryotic initiation factor 2 phosphorylation. J. Biol. Chem. 258:7928-7934.
20. Mundschau, L.J., and Faller, D.V. 1992. Oncogenic ras induces an inhibitor ot double-stranded RNA-dependent eukaryotic initiation factor 2 alpha-kinase activation. J. Biol. Chem. 267:23092-23098.
21. Mundschau, L.J. and Faller, D.V. 1994. Endogenous inhibitors of the dsRNA-dependent elF-2 alpha protein kinase PKR in normal and ras-transformed cells. Biochimie. 76:792-800.
22. Williams, M.E., Cox, D.C., and Stevenson, J.R. 1986. Rejection of reovirus-treared L1210 leukemia ceils by mice. Cancer Immunol. Immunother. 23:87-92.
23. Steele, T.A., and Cox, D.C. 1995. Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine. Cancer Biother. 10:307-315.
24. Forrester, K., Almoguera, C., Han, K., Grizzle, W.E., and Perucho, M. 1987. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 327:298-303.
25. Bos, J.L., et al. 1987. Prevalence of ras gene mutations in human colorectal cancers. Nature. 327:293-297.
26. Beaupre, D.M., and Kurzrock, R. 1999. RAS and leukemia: from basic mechanisms to gene-directed therapy. J. Clin. Oncol. 17:1071-1079.
27. Almoguera, C., et al. 1988. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 53:549-554.
28. Brison, O. 1993. Gene amplification and tumor progression. Biochim. Biophys. Acta. 1155:25-41.
29. Bredel, M., and Pollack, I.F. 1999. The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Brain Res. Brain Res. Rev. 29:232-249.
30. Slamon, D.J., et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:707-712.
31. Kim, H., and Muller, W.J. 1999. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp. Cell Res. 253:78-87.
32. Ottenhoff-Kalff, A.E., et al. 1992. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res. 52:4773-4778.
33. Zou, X., and Calame, K. 1999. Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J. Biol. Chem. 274:18141-18144.